Dr. August Wolff GmbH & Co. KG Arzneimittel
20
1
1
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
10.0%
2 terminated/withdrawn out of 20 trials
88.9%
+2.4% vs industry average
25%
5 trials in Phase 3/4
6%
1 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (20)
Testing the Protective and Caring Effect of a Water-in-oil Formulation in Patients Suffering From Urinary and/or Fecal Incontinence and Requiring Incontinence Care Products
Role: lead
Clinical Trial of a Mouth and Throat Rinse for the Treatment of Acute Sore Throat
Role: lead
Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary Hyperhidrosis
Role: lead
Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis
Role: lead
In-Use Test of a Cosmetic Product in Subjects With Chronically Itchy Scalp
Role: lead
In-Use Test With a Cosmetic Product to Treat Pruritus
Role: lead
Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in Patients With Primary Axillary Hyperhidrosis.
Role: lead
Investigation of Efficacy and Tolerability of WO 2707, a MoistCream Cremolum, in Postmenopausal Women Suffering From Symptoms of Vaginal Dryness
Role: lead
Investigation of Efficacy and Tolerability of a Lactic Acid Containing Vaginal Suppository in Post-menopausal Women With VVA
Role: lead
Use Test: Dermowas Body Lotion pH 4 vs. pH 5.8
Role: lead
Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis
Role: lead
Assessment of the Efficacy and Barrier Protection of Two Cosmetic Products
Role: lead
Investigation on the Efficacy of WO 2085 Moisturising Cream for Breast Cancer Patients Suffering From Vulvovaginal Dryness
Role: lead
Efficacy and Safety of Non-hormonal Vaginal Preparations in Treating Vaginal Dryness
Role: lead
In-Use Test With a Cosmetic Product
Role: lead
Investigation of Non-inferiority of Treatment of Vulvovaginal Dryness With WO2085 Moisturising Cream in Comparison to a Cream With 0.1% Estriol
Role: lead
Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy
Role: collaborator
Safety, Tolerability and Efficacy of Vaginal Suppository WO3191 in the Post-treatment of Bacterial Vaginosis
Role: lead
Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients
Role: lead
Three-Year Trial on a New Testosterone Gel
Role: collaborator
All 20 trials loaded